98%
921
2 minutes
20
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.blre.2025.101272 | DOI Listing |
Crit Rev Ther Drug Carrier Syst
January 2025
Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Cancer stem cells (CSCs) are a category of cancer cells endowed with the ability to renew themselves, undergo unregulated growth, and exhibit a differentiation capacity akin to that of normal stem cells. CSCs have been linked with tumor metastasis and cancer recurrence due to their ability to elude immune monitoring. As a result, targeting CSCs specifically may improve the efficacy of cancer therapy.
View Article and Find Full Text PDFJ Vis Exp
August 2025
The Ragon Institute of Mass General, MIT, and Harvard Main Street;
Ultraviolet B (UVB) radiation (280-320 nm) has been recognized as a carcinogen since 1928, leading to sun exposure minimization. However, epidemiological studies suggest that sun exposure correlates with increased life expectancy and reduced incidence of cardiovascular diseases and certain cancers such as colon and endometrial cancer. UVB exposure also influences liver metabolism, protects against hepatocellular lipotoxicity, and affects metabolic health.
View Article and Find Full Text PDFJ Infect Dev Ctries
August 2025
Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa; Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa; Geminii, Inc.
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease.
View Article and Find Full Text PDFJ Thorac Oncol
July 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: TNM staging systems create prognostic categories by anatomic extent of disease. Whether therapeutically important molecular alterations in NSCLC augment the prognostic information of TNM staging is unclear. To study this, we analyzed molecular data from the ninth edition of the lung cancer staging system.
View Article and Find Full Text PDF